Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 14/20 | 0.63 |
| ▸ | PDE4D | Q08499 | 11/20 | 0.45 |
| ▸ | PDE4A | P27815 | 9/20 | 0.45 |
| ▸ | PDE4C | Q08493 | 9/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | EIF2AK1 | Q9BQI3 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4363637 | 0.78 | PDE4B (1.00) | PDE4BPDE4DPDE4APDE4C | |
| SCHEMBL4365529 | 0.73 | PDE4B (0.56) | PDE4BPDE4DPDE4APDE4CNPSR1 | |
| SCHEMBL3675674 | 0.72 | PDE4B (0.82) | PDE4BPDE4DPDE4APDE4C | |
| SCHEMBL4375614 | 0.71 | PDE4B (0.55) | PDE4BPDE4DPDE4APDE4C | |
| SCHEMBL3672452 | 0.70 | PDE4B (0.73) | PDE4BPDE4DPDE4APDE4C | |
| SCHEMBL4369467 | 0.69 | PDE4B (0.53) | PDE4BPDE4DPDE4APDE4C | |
| SCHEMBL3670633 | 0.69 | PDE4B (0.74) | PDE4BPDE4DPDE4APDE4C | |
| SCHEMBL4364149 | 0.69 | PDE4B (0.53) | PDE4BPDE4DPDE4APDE4C | |
| SCHEMBL3672733 | 0.69 | PDE4B (0.70) | PDE4BPDE4DPDE4APDE4C | |
| SCHEMBL4369320 | 0.68 | PDE4B (0.69) | PDE4BPDE4DPDE4APDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090291950-A1 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | KALYPSYS, INC. (US) | 2009-11-26 | — | — | US | disclosed |
| US-20090291950-A1 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | KALYPSYS, INC. (US) | 2009-11-26 | — | — | US | disclosed |
| US-20090291950-A1 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | KALYPSYS, INC. (US) | 2009-11-26 | — | — | US | disclosed |
| WO-2008006052-A2 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | GOVEK STEVEN P (US) | 2008-01-10 | — | — | WO | disclosed |
| WO-2008006052-A2 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | GOVEK STEVEN P (US) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291950-A1 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | PDE4A, PDE4B, PDE4C | PDE4B 2/4885PDE4D 4/4885PDE4A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.